Applied Therapeutics Shares Hit 52-Week High on Govorestat Filings
By Colin Kellaher
Applied Therapeutics shares rose sharply and hit a new 52-week high on Wednesday after the clinical-stage biopharmaceutical company reported a pair of regulatory advances for its lead product candidate.
Shares of the New York company were recently changing hands at $3.98, up 9.2%, after touching a 52-week high of $4.42 earlier in the session.
Applied said it filed last month for U.S. Food and Drug Administration approval of govorestat for the treatment of classic galactosemia, a rare genetic metabolic disease for which there is currently no available treatment.
The company also said the European Medicines Agency has validated and accepted for review its application seeking approval of the drug in the European Union.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 03, 2024 11:05 ET (16:05 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying